Orexin receptor · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Orexin receptor shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt O43614. Start with insomnia, then reuse UniProt O43614 as the stable protein anchor across project notes and exports.
Start with insomnia, then reuse UniProt O43614 as the stable protein anchor across project notes and exports.
Orexin receptor shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.
Start review with insomnia because it currently carries approved-linked support. Linked drugs include ALMOREXANT, DARIDOREXANT, FILOREXANT, ORN-0829 HYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyOrexin receptor type 2
Review this target as Orexin receptor, mapped to UniProt O43614. ChEMBL maps the protein component as Orexin receptor type 2. Sequence length is 444 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Orexin receptor as ChEMBL target CHEMBL3307226, mapped to UniProt O43614. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Orexin receptor is the right protein anchor across sources, using UniProt O43614 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why insomnia is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Orexin receptor |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | O43614 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Orexin receptor type 2 |
| UniProt Accession | O43614 |
| Component Type | Protein |
| Sequence Length | 444 aa |
Orexin receptor type 2
Review this target as Orexin receptor, mapped to UniProt O43614. ChEMBL maps the protein component as Orexin receptor type 2. Sequence length is 444 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Orexin receptor shows approved-linked disease relevance led by insomnia. 5 more disease programs remain visible in the same review block.
Start review with insomnia because it currently carries approved-linked support. Linked drugs include ALMOREXANT, DARIDOREXANT, FILOREXANT, ORN-0829 HYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.